Treatment with myriocin increased NE invaginations in the BRCA1-deficient p53-deficient breast cancer cell line HCC-1937 and the effect of PARPi in compromising their survival (Fig. 5a–c and Supplementary Fig. 5a, b). Here, TP53 is linked to breast carcinoma.